He or she also may prescribe bisphosphonate drugs, which include alendronate (Fosamax[R]),
ibandronate (Boniva[R]), risedronate (Actonel[R]), and zoledronic acid (Reclast[R]), or other osteoporosis treatments such as denosumab (Prolia[R]), or teripara5 tide (Forteo[R]).
Treatment with zoledronate 6 months after the last denosumab injection achieves partial preservation of BMD, but multiple vertebral fractures have still been reported when raloxifene,
ibandronate, or alendronate have been given after stopping denosumab, she said.
Bisphosphonates, which include alendronate (Fosamax), risedronate (Actonel), zoledronic acid (Reclast), and
ibandronate (Boniva) are recommended as the initial treatment.
Osteopenia treatment includes medications, which include bisphosphonate medications, such as
ibandronate (Boniva), alendronate (Fosamax), risedronate (Actonel), zoledronate (Reclast) and raloxifene (Evista).
Bisphosphonates are mainly of two sub classes, non Nitrogen containing like Etidronate, Clodronate, Tiludronate and Nitrogen containing bisphosphonates Pamidronate, Nerid-ronate, Olpadronate, Alendronate,
Ibandronate, Risedronate.
In terms of percentage BMD change at the femoral neck, both pamidronate and
ibandronate combined with calcium demonstrated a remarkable gain compared with calcium (MD, 7.02; 95% CrI, 0.30-13.29 and MD, 7.30; 95% CrI, 0.32-14.22, respectively).
Medications include the following: lisinopril/hydrochlorothiazide (Prinzide[R]) 20 mg/12.5 mg by mouth daily, aspirin 81 mg by mouth daily, atorvastatin (Lipitor[R]) 20 mg by mouth at night, metformin (Glucophage[R]) 500 mg by mouth twice daily, ergocalciferol 800 units orally once daily, and
ibandronate (Boniva[R]) 150 mg every month.
Oral daily or quarterly intravenous injection of
ibandronate decreases serum CTX by 53.4% to 59.9% [15].
Bisphosphonate drugs, such as alendronate (Fosamax),
ibandronate (Boniva) and zoledronic acid (Reclast), are proven to combat bone loss and fractures in people with the bone-thinning disease osteoporosis.
With regard to spontaneous osteonecrosis of the knee,
ibandronate was used in a retrospective double-blind study conducted by Meier and associates.
She had been taking a bisphosphonate--oral
ibandronate sodium, 150 mg, once monthly--for about 6 years.